Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Delaet Ingrid sold 14,571 Neurocrine Biosciences, Inc. shares (Form 4)
Traded Jul 7 to Jul 9, 2026 · Filed Jul 9, 2026
From Jul 7 to Jul 9, 2026, Delaet Ingrid (Chief Regulatory Officer) sold 14,571 Neurocrine Biosciences, Inc. shares at an average US$178.65 for US$2.6M under a trading plan, leaving 16,225 shares. Filed Jul 9, 2026 (Form 4).
- Sold
- 14,571 shares
- Price
- US$178.65 average (US$178.54 to US$178.72)
- Value
- US$2.6M
- Holding after
- 16,225 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Regulatory Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | Option exercise | 3,401 | US$103.52 | 19,626 | Direct |
| Jul 7, 2026 | Common Stock | Sale | 3,401 | US$178.57 | 16,225 | Direct |
| Jul 8, 2026 | Common Stock | Option exercise | 2,737 | US$103.52 | 18,962 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 2,737 | US$178.54 | 16,225 | Direct |
| Jul 9, 2026 | Common Stock | Option exercise | 8,433 | US$103.52 | 24,658 | Direct |
| Jul 9, 2026 | Common Stock | Sale | 8,433 | US$178.72 | 16,225 | Direct |
Source
Related
- Neurocrine Biosciences, Inc.
- Delaet Ingrid
- Neurocrine Biosciences, Inc. shareholders
- Form 4 · Delaet Ingrid · Sep 15, 2026
- Form 4 · Delaet Ingrid · Jul 13, 2026
- Form 4 · Delaet Ingrid · Jun 2, 2026
- Schedule 13G/A · JPMorgan Chase & Co · Oct 15, 2026
- Form 4 · Boyer David W. · Sep 15, 2026
- Form 4 · Abernethy Matt · Sep 15, 2026
- Form 4 · Gano Kyle · Sep 15, 2026
- Form 4 · Onyia Jude · Sep 15, 2026